Consensus Tarsus Pharmaceuticals, Inc.

Stocks

TARS

US87650L1035

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 17/10/2026 am IST			5-day change	1st Jan Change
68.07 ^USD	-4.11%		-6.96%	-16.87%

18/09	Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing	MT
10/09	Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing	MT

Evolution of the Average Target: Tarsus Pharmaceuticals, Inc.

Evolution of the Target Price: Tarsus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Tarsus Pharmaceuticals, Inc.

4dd3e956.pzACAWscXOyitrHdUgSYgo-oMxEU-__07km45bm79Eo.33ppRyRGGIjJ0cKMI1z02NztQFVmqoeD1yXKsej5nADOR2VTGFUqhfr_0g~53960c859e368bc072ee0323c15870ac

Analysts' recommendations: Tarsus Pharmaceuticals, Inc.

12/08	Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating	MT
07/08	Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating	MT
31/07	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating	MT
24/04	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating	MT
23/04	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $100 From $101, Keeps Outperform Rating	MT
26/03	Mizuho Lifts Price Target on Tarsus Pharmaceuticals to $101 From $100, Keeps Outperform Rating	MT
25/02	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating	MT
20/11	Mizuho Initiates Tarsus Pharmaceuticals at Outperform With $100 Price Target	MT
09/25/09	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
09/25/09	BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80	MT
07/25/07	Tarsus Pharmaceuticals Q2 revenue beats expectations	RE
02/25/02	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating	MT
03/25/03	BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74	MT
22/25/22	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $72 From $65, Keeps Outperform Rating	MT
14/24/14	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	MT
09/24/09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating	MT
09/24/09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT
29/24/29	Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating	MT
28/24/28	Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating	MT
20/23/20	Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target	MT
10/23/10	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $42, Keeps Buy Rating	MT
11/23/11	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $49 From $46, Maintains Buy Rating	MT
11/23/11	HC Wainwright Adjusts Tarsus Pharmaceuticals Price Target to $42 From $50, Maintains Buy Rating	MT
26/23/26	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $44, Maintains Buy Rating	MT
18/23/18	William Blair Initiates Tarsus Pharmaceuticals at Outperform Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TARSUS PHARMACEUTICALS, INC.					+46.61%
	ELI LILLY AND COMPANY					+5.65%
	JOHNSON & JOHNSON					+9.33%
	ABBVIE INC.					-0.99%
	ROCHE HOLDING AG					-0.52%
	MERCK & CO., INC.					+8.56%
	NOVARTIS AG					-0.8%
	ASTRAZENECA PLC					+26.78%
	AMGEN INC.					-8.67%
	GILEAD SCIENCES, INC.					+2.34%
	Average					+8.83%
	Weighted average by Cap.					+5.00%